Main menu

Press Release Archive

Press Release Archive

 
September 16, 2012 - Pfizer To Present New Data in Lung And Kidney Cancers at The European Society For Medical Oncology 2012 Congress

(BUSINESS WIRE)--Pfizer Oncology today announced that important data from its lung cancer and renal cell carcinoma (RCC) portfolios will be presented at the upcoming European Society for Medical Oncology (ESMO) Congress in Vienna, Austria, September 28 – October 2, 2012. “We believe that the clinical trial results to be shared at ESMO 2012 substantially enhance our knowledge of both marketed and investigational therapies from our lung and kidney cancermore...

 
September 13, 2012 - Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference

(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Mikael Dolsten, President, Worldwide Research and Development, at the UBS Global Life Sciences Conference on Thursday, September 20, 2012 at 9:00 a.m. Eastern Daylight Saving Time. To view and listen to the webcast, visit our web site at www.pfizer.com and click on the “UBS Global Life Sciences Conference” link in Tab 2 of themore...

 
September 13, 2012 - Pfizer Recognized by Carbon Disclosure Project for Carbon Performance

(BUSINESS WIRE)--Pfizer (NYSE: PFE) announced that it has been commended by the Carbon Disclosure Project (CDP) for the actions it is taking to reduce emissions and mitigate the risks of climate change. For the first time, CDP named Pfizer to its Carbon Performance Leadership Index (CPLI), which highlights those companies within the FTSE Global Equity Index Series (Global 500) and the S&P 500 Index that have demonstrated a strong approach to climate strategymore...

 
September 12, 2012 - Pfizer and Waste Management Launch Online Pharmaceutical Disposal Guide

(BUSINESS WIRE)--Pfizer (NYSE: PFE) and WM Healthcare Solutions, Inc., a subsidiary of Waste Management, Inc., (NYSE: WM) today jointly announced the introduction of a new, free-of-charge, online pharmaceutical disposal guide for health care providers and facilities called the “Pfizer Responsible Disposal Advisor®.” Pfizer is the first pharmaceutical company to make this resource available to health care professionals to help guide them through sometimes complexmore...

 
September 12, 2012 - Pfizer And Hisun Announce Launch Of Hisun-Pfizer Pharmaceuticals Co., Ltd.

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE), the world’s largest research-based pharmaceutical company, and Zhejiang Hisun Pharmaceuticals (SSE Code: 600267), a leading Chinese pharmaceutical company, today announced the launch of Hisun-Pfizer Pharmaceuticals Co., Ltd. (hereafter referred to as Hisun-Pfizer), a joint venture formed between the two companies to develop, manufacture and commercialize off-patent pharmaceutical products in China and global markets. Themore...

 
September 10, 2012 - World Health Organization Grants Expansion To The Prequalification For Prevenar 13 To Include Adults 50 Years Of Age And Older

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the World Health Organization (WHO) has granted an expansion to the prequalification of Pfizer’s pneumococcal conjugate vaccine, Prevenar 131 (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]), to include adults 50 years of age and older against pneumonia and invasive disease caused by the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) contained in

 
September 6, 2012 - Pfizer Settles Patent Litigation with Mylan Covering Detrol LA®

(BUSINESS WIRE)--Pfizer Inc. announced that it has settled its litigation against Mylan Inc. and Mylan Pharmaceuticals Inc. relating to Pfizer’s patents covering Detrol LA® (tolterodine tartrate) extended-release capsules. As a result of this settlement, and past settlements related to these patents, Pfizer expects generic competition for Detrol LA® to commence in the United States no earlier than January 1, 2014, except in certain limited circumstancesmore...

 
September 4, 2012 - U.S. Food and Drug Administration Approves BOSULIF® (bosutinib) for Patients with Previously Treated Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia (CML)

(BUSINESS WIRE)--Pfizer Inc. announced today the U.S. Food and Drug Administration (FDA) has approved BOSULIF® (bosutinib), an Abl and Src kinase inhibitor, for the treatment of adult patients with chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance, or intolerance to prior therapy. Patients in the registrational trial included patients who were previously treated with imatinib [Gleevecmore...

 
September 4, 2012 - Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At Healthcare Conference

(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Frank D’Amelio, Executive Vice President, Business Operations and Chief Financial Officer, at the Morgan Stanley Global Healthcare Conference on Tuesday, September 11, 2012 at 9:10 a.m. Eastern Daylight Time. To listen to the webcast, visit our web site at www.pfizer.com and click on the “Morgan Stanley Global Healthcare Conference” link inmore...

 
September 3, 2012 - Pfizer Receives EU Marketing Authorization for INLYTA® (Axitinib)

(BUSINESS WIRE)--Pfizer Inc. announced today that the European Commission (EC) has granted marketing authorization for INLYTA® (axitinib) for the treatment of adult patients with advanced renal cell carcinoma (RCC), a type of kidney cancer, after failure of prior treatment with sunitinib or a cytokine. INLYTA, a kinase inhibitor, is an oral therapy that was designed to selectively inhibit vascular endothelial growth factor (VEGF) receptors 1, 2more...

 
August 30, 2012 - Spiriva® HandiHaler® (tiotropium bromide inhalation powder) and COPD Data to be Presented at the 2012 European Respiratory Society (ERS) Congress

(BUSINESS WIRE)--Boehringer Ingelheim and Pfizer Inc (NYSE: PFE) announced today three scientific data presentations will take place at the 2012 European Respiratory Society (ERS) Congress in Vienna, Austria, Sept. 1-5, 2012. SPIRIVA & Exercise Capacity Study (205.440) Primary data from a new randomized, double-blind cross-over trial (205.440) comparing outcomes of treadmill exercise testing in patients with chronic obstructive pulmonarymore...

 
August 27, 2012 - Pfizer Announces Conclusion of Consent Solicitation For $22.5 Million of Debt

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the results of its solicitation of consents to amend certain provisions of the indentures with respect to the following outstanding debt securities of its wholly-owned subsidiary Pharmacia Corporation: Debt Security   CUSIP No.   Outstanding PrincipalAmountmore...

 
August 23, 2012 - Pfizer Announces Successful Consent Solicitation Results For Three Series Of Debt

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the results of its solicitation of consents to amend certain provisions of the indentures with respect to the following outstanding debt securities of its wholly-owned subsidiary Pharmacia Corporationmore...

 
August 20, 2012 - U.S. Food And Drug Administration Extends Action Date For Tofacitinib New Drug Application By Three Months

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has extended the action date by three months for the New Drug Application (NDA) for tofacitinib, an investigational oral treatment for adults with moderately to severely active rheumatoid arthritis (RA). If approved, tofacitinib would be the first RA treatment in a new class of medicines known as Janus kinase (JAK) inhibitors and the first new oral disease-more...

 
August 20, 2012 - ELIQUIS® (apixaban) Data Analyses To Be Presented At European Society of Cardiology Congress 2012

(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced that multiple data presentations on ELIQUIS® (apixaban) will be presented at the European Society of Cardiology Congress 2012, August 25-29, 2012, in Munich, Germany. New data will be presented, including a prespecified subanalysis from the ARISTOTLE trial that evaluated the efficacy and safety of ELIQUIS compared to warfarin in relation to renal functionmore...

 
August 15, 2012 - Pfizer Commences Consent Solicitation for Amendments to Pharmacia Indentures

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that it has commenced a consent solicitation to amend certain provisions of the indentures governing the following outstanding debt securities (the Securities) of Pharmacia Corporation, its wholly-owned subsidiary: Debt Security Description     CUSIP Nomore...

 
August 13, 2012 - Pfizer And Astrazeneca Enter Into Agreement For Over-The-Counter Nexium

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that it has entered into an agreement with AstraZeneca for the over-the-counter (OTC) rights for NEXIUM (esomeprazole magnesium), a leading prescription drug currently approved to treat the symptoms of gastroesophageal reflux disease (GERD). Under the terms of the agreement, Pfizer will acquire the exclusive global rights to market NEXIUM for the approved over-the-counter indications in the United States,more...

 
August 12, 2012 - Zoetis™ Files IPO Registration Statement

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its subsidiary, Zoetis™ Inc. (zō-EH-tis), filed a registration statement with the U.S. Securities and Exchange Commission for a potential initial public offering (IPO) of Class A common stock. The offering is expected to represent an ownership stake of up to 20 percent. Prior to completion of the offering, which is targeted for the first half of 2013, Pfizer will transfer its animal health business tomore...

 
August 9, 2012 - Pfizer Reports Results From Phase 3 Study Of Torisel (temsirolimus) In Combination With Bevacizumab In Advanced Renal Cell Carcinoma (RCC)

(BUSINESS WIRE)--Pfizer Inc. announced today that the Phase 3 INTORACT trial (B1771006), evaluating the combination of bevacizumab plus TORISEL® (temsirolimus) compared with bevacizumab plus interferon-alfa-2a (IFN-α-2a) in the first-line treatment of patients with advanced renal cell carcinoma (RCC) across risk groups, did not meet its primary endpoint of superiority in extending progression free survival (PFS) in the study population. Additional efficacymore...

 
August 8, 2012 - Pfizer Reduces Its Greenhouse Gas Emissions by 20 Percent

(BUSINESS WIRE)--Pfizer today announced that it achieved its five-year public goal of reducing greenhouse gas (GHG) emissions by 20 percent after only four years. As a result of this effort, the company achieved $85 million in annualized project savings. This milestone marks the second time since 2000 that Pfizer has reached its target of cutting GHG emissions. ”Environmental sustainability is aligned with Pfizer’s strategic business imperatives,more...

Pages

Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.

 

Stock Quote Disclaimer

20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.

pdf

If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.

Current Stock Price

. .
.
%Change . 52 Wk. High .
Day High . 52 Wk. Low .
Day Low . Mkt. Cap(Mil) .
Open .    
Prev Close . Symbol .
Vol. . Exchange .

Online Pfizer Press Kit

Our press kit provides information that might help you write stories or simply find out more about Pfizer.